

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 01:44:02 +0000
To: Johnson, Carolyn
Cc: Collins, Francis (NIH/OD) [E] (b) (6) Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Washington Post
Attachments: NIAID COVID-19 Strategic Plan Final 10April 2020.docx

Carolyn:

Thanks for the note. I understand that you will be hearing from Francis Collins on the Public Private Partnership (PPP) that we have put together to combine the resources and assets of industry and the academic community that is largely supported by NIH, particularly NIAID in the context of COVID-19. It is the functional equivalent of a National Strategy. We at NIAID and to some extent other institutes are leveraging our vast clinical trials networks that we built for other infectious diseases, particularly, but not exclusively HIV/AIDS, to provide the capacity to conduct clinical trials (NIH-sponsored as well as industry-sponsored) for both vaccines and therapeutics for COVID-19. For your interest, I am attaching a copy (not yet released) of the NIAID Strategic Plan for COVID-19 Research. It is an outline that will be supplemented with an implementation plan.

Best regards,
Tony

From: Johnson, Carolyn <Carolyn.Johnson@washpost.com>
Sent: Tuesday, April 14, 2020 10:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Washington Post

Dear Tony,

Is there a national strategy at the task force level to coordinate clinical research efforts nationally? We have heard lots of complaints that there isn't a national strategy. I talked to Cliff Lane about this, but we want to give you the chance to respond.

Carolyn

Carolyn Johnson
Washington Post
202-334-6248 (desk)
(b) (6) (cell)